Welcome to our dedicated page for Carmell Corporation Warrant news (Ticker: CTCXW), a resource for investors and traders seeking the latest updates and insights on Carmell Corporation Warrant stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Carmell Corporation Warrant's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Carmell Corporation Warrant's position in the market.
Carmell (NASDAQ: CTCX) announced a corporate rebranding to Longevity Health Holdings, with new trading symbols XAGE and XAGEW effective March 10, 2025. The rebranding reflects the company's expanded focus on longevity and healthy aging, including bio-aesthetics, diagnostics, and nutrition.
Following the January 2025 acquisition of Elevai Skincare, combined sales grew 34% in the first two months of 2025 compared to 2024. The company reduced Elevai's burn rate by 50% through overhead cost savings, while doubling the physician-focused salesforce. FY25 revenue guidance is projected at $3-4 million from current products.
The company plans to launch four new products in Q2 2025: Hair Growth Serum, Soapless Facial Cleanser, Undereye Crème, and VSA Toning Moisturizer. Additionally, Patrick Sturgeon, a founding team member and former CFO, has been appointed as Vice Chairman.
